EMA Recommends Granting a Marketing Authorisation for Generic Trabectedin By Ogkologos - April 30, 2025 511 0 Facebook Twitter Google+ Pinterest WhatsApp Trabectedin Accord is a generic of Yondelis, which has been authorised in the EU since 2007 Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Can Topical Drugs Help Prevent Breast Cancer? December 4, 2018 Grandparents of children with cancer: “I would never want to go... September 1, 2020 Olaparib Plus Bevacizumab Provides Clinically Meaningful OS Improvement for Newly Diagnosed... May 31, 2023 Getting cancer services back on track during the COVID-19 pandemic June 22, 2020 Load more HOT NEWS Study Shows That Fast-Mimicking Diets Are Safe and Effective for Patients... Adjuvant Atezolizumab Plus Bevacizumab Improves RFS Among Patients at High Risk... EMA Recommends Granting a Marketing Authorisation for Vorasidenib Telephone-Based Rehab Program Helps People with Advanced Cancer Maintain Independence
